ENDPOINTS

SEC expected to drop investigation of Illumina's $8B Grail deal

The SEC is expected to drop an investigation into Illumina's $8 billion acquisition of cancer test developer Grail, Endpoints News has learned. In 2023, Illumina disclosed in a regulatory filing that the ...

May 6, 2025 - 19:58
 0
SEC expected to drop investigation of Illumina's $8B Grail deal
The SEC is expected to drop an investigation into Illumina's $8 billion acquisition of cancer test developer Grail, Endpoints News has learned. In 2023, Illumina disclosed in a regulatory filing that the ...
Read More

Tags:

Previous Article

SpaceX's Starbase becomes a city

Next Article

Meet The Lectric XP4: A Folding E-Bike That Doesn’t Compromise

Related Posts

How pharma is reacting to ‘Liberation Day’: Endpoints livestream

How pharma is reacting to ‘Liberation Day’: Endpoints l...

Apr 29, 2025  0

Cassidy urges major reforms to 340B drug discount program

Cassidy urges major reforms to 340B drug discount program

Apr 24, 2025  0

Gilead Q1 earnings: Strong HIV business balances out low Covid and cancer drug sales

Gilead Q1 earnings: Strong HIV business balances out lo...

Apr 25, 2025  0